Funder
National Science Foundation
Division of Chemical, Bioengineering, Environmental and Transport Systems
Reference252 articles.
1. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia;Park;N. Engl. J. Med.,2018
2. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib;Turtle;J Clin Oncol,2017
3. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells;Lee,2019
4. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature reviews clinical oncology;Rafiq;Nature Research March,2020
5. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit “ALL.” nature reviews clinical oncology;Teachey;Nature Publishing Group April,2018